Results 51 to 60 of about 23,896 (206)

Eosinophils Target Therapy for Severe Asthma: Critical Points [PDF]

BioMed Research International, 2018
Asthma is a chronic and heterogeneous disease, which is defined as severe disease whenever it requires treatment with a high dose of inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming ‘‘uncontrolled’’ or if it remains ‘‘uncontrolled’’ despite this therapy.
Brussino, L., Heffler, E., Bucca, C., Nicola, S., Rolla, G.   +4 more
openaire   +3 more sources

Severe eosinophilic asthma in Chinese C‐BIOPRED asthma cohort [PDF]

Clinical and Translational Medicine, 2022
Qingling Zhang, Xiuhua Fu, Changzheng Wang, Huahao Shen, Lei Zhu, Guochao Shi, Zhongmin Qiu, Zhongguang Wen, Wei Gu, Wei Luo, Lina Zhao, Yunqin Chen, Sam Lim, Chang Xiao, Jian Kang, Yunhui Zhang, Mao Huang, Jinfu Xu, Kewu Huang, Qiang Li, Xiangyan Zhang, Jianping Zhao, Xiaoxia Liu, Shenghua Sun, Huaping Tang, Bei He, Shaoxi Cai, Ping Chen, Chunhua Wei, Guangfa Wang, Ping Chen, Lixin Xie, Jiangtao Lin, Yuling Tang, Zhihai Han, Kian Fan Chung, Nanshan Zhong, the C‐BIOPRED consortium   +37 more
openaire   +3 more sources

Aerodigestive evaluation in patients with eosinophilic asthma

Respiratory Medicine Case Reports
We present two pediatric patients with severe uncontrolled asthma who underwent aerodigestive evaluation revealing eosinophilic asthma and eosinophilic esophageal inflammation.
Chloe Citron, Jessica Erkman, Mikhail Kazachkov, Anna Nowak-Wegrzyn, Deniz Kesebir   +4 more
doaj   +1 more source

The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma

Advances in Respiratory Medicine
Background: Severe asthma is associated with significant morbidity and risk of complications. Some patients, suffering from eosinophilic asthma, may benefit from biological therapies, especially anti IL-5 (anti-interleukin-5).
Aleksandra Niemiec-Górska, Olga Branicka, Paula Olszewska, Sylwia Mielcarska, Joanna Glück, Barbara Rymarczyk, Radosław Gawlik   +6 more
doaj   +1 more source

Clinical usefulness of mepolizumab in severe eosinophilic asthma

Therapeutics and Clinical Risk Management, 2016
Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis
Menzella, Francesco, Lusuardi,Mirco, Montanari,Gloria, Galeone,Carla, Facciolongo,Nicola, Zucchi,Luigi   +5 more
openaire   +5 more sources

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports [PDF]

, 2021
Laura Pini, Cristiano Caruso, Stefania Colantuono, Diego Bagnasco, Aoife C. Maxwell, Robert G. Price, Peter Howarth, Giorgio Walter Canonica, Italian investigators of REALITI‐A   +8 more
openalex   +1 more source

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report

Journal of Medical Case Reports
Background The advent of biologics has resulted in major progress in the treatment of severe T2 high asthmatics. There are currently several classes of biologics approved for severe asthma including anti-immunoglobulin E, anti-interleukin-5/interleukin ...
M. Sabbe, F. Schleich, P. Janssens, R. Louis   +3 more
doaj   +1 more source

MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA [PDF]

Chest, 2020
Q. Shahzad, M. Zaheer
openaire   +1 more source

Severe Asthma—Perspectives From Adult and Pediatric Pulmonology

Frontiers in Pediatrics, 2019
Both adults and children with severe asthma represent a small proportion of the asthma population; however, they consume disproportionate resources. For both groups it is important to confirm the diagnosis of severe asthma and ensure that modifiable ...
Louise Fleming, Liam Heaney
doaj   +1 more source

Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial

ERJ Open Research
Background Severe asthma affects the working life of millions of people worldwide. Interleukin (IL)-5/anti-interleukin-5 receptor α (IL-5Rα) antibodies are highly effective in reducing symptoms in patients with severe eosinophilic asthma.
Lina Brinkmann, Jan Fuge, Tobias Welte, Hendrik Suhling, Nora Drick   +4 more
doaj   +1 more source